Amicus Therapeutics (FOLD)
(Real Time Quote from BATS)
$9.74 USD
+0.38 (4.06%)
Updated May 30, 2024 01:18 PM ET
4-Sell of 5 4
F Value A Growth F Momentum C VGM
Amicus Therapeutics (FOLD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.30 | $21.00 | $13.00 | 84.83% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Amicus Therapeutics comes to $17.30. The forecasts range from a low of $13.00 to a high of $21.00. The average price target represents an increase of 84.83% from the last closing price of $9.36.
Analyst Price Targets (10)
Broker Rating
Amicus Therapeutics currently has an average brokerage recommendation (ABR) of 1.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 10 recommendations.
Of the 11 recommendations deriving the current ABR, nine are Strong Buy, representing 81.82% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.36 | 1.36 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
5/10/2024 | Needham & Company | Gil J Blum | Hold | Hold |
2/29/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
1/8/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.36 |
ABR (Last week) | 1.36 |
# of Recs in ABR | 11 |
Average Target Price | $17.30 |
LT Growth Rate | 45.50% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 90 of 252 |
Current Quarter EPS Est: | -0.05 |